Business Wire

NY-CITI

2.11.2020 14:02:05 CET | Business Wire | Press release

Share
Citi Selected as Financial Advisor to Gavi, The Vaccine Alliance’s COVAX Facility

Citi today announced the firm has been selected by Gavi, the Vaccine Alliance, to be the financial advisor for the COVAX Facility, its global procurement mechanism for COVID-19 vaccines.

The COVAX Facility is part of COVAX , a global, multilateral initiative aimed at developing, manufacturing and deploying COVID-19 vaccines on a fair and equitable basis. It is co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) , and the World Health Organization (WHO) – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, Civil Society Organizations and others.

Citi will provide Gavi with expert advice on structures to mitigate sovereign, credit and operational risk as the COVAX Facility seeks to facilitate pooled procurement and equitable distribution of safe and effective COVID-19 vaccines from multiple pharmaceutical manufacturers to all COVAX participating economies once they reach licensure.

“Citi considers this assignment to be a clear demonstration of who we are as a firm and it builds on the work we’re doing to help combat this crisis on many fronts,” said Jane Fraser, President of Citigroup and CEO of Global Consumer Banking. “Funding of vaccines is at the core of bringing this crisis to an end, and Citi is honored to contribute to this unprecedented effort. We are bringing top talent together from around the firm to support Gavi in achieving its global objectives.”

In its first phase, and up until the end of 2021, the COVAX Facility aims to secure and deliver 2 billion doses of vaccines to be distributed to member countries’ populations. The facility currently counts over 180 sovereign government entities as participants.

In its role as advisor, Citi will advise and assist in finding risk mitigation and execution strategies in connection with the facility, including supporting the building of strategies to operationalize and maintain the COVAX Facility.

“COVAX represents the best chance to provide people in all countries with rapid, fair and equitable access to COVID-19 vaccines as soon as they become available. We’re delighted to engage Citi, allowing the COVAX Facility to benefit from expert external advice to complement our in-house expertise, supporting our essential work mitigating risk and structuring the COVAX Facility to be as effective as possible,” said Dr. Seth Berkley, Chief Executive Officer, Gavi.

Throughout the pandemic, Citi has worked closely with governments and the private sector to find liquidity alternatives and funding solutions in response to COVID-19. This has included large targeted development bank and NGO efforts for the pandemic, including COVID-19 emergency programs by the World Bank, Africa Development Bank, the New Development Bank, and Gavi’s own International Finance Facility for Immunisation (IFFIm), where Citi recently acted as joint bookrunner on its $500m vaccine bond.

“Just, rapid and efficient funding and distribution of COVID-19 vaccines remains our best hope of ending this crisis, and we are committed to optimizing the COVAX Facility for that purpose, said Jay Collins, Vice Chairman, Banking, Capital Markets and Advisory at Citi and the lead advisor for the Citi team. “The size and complexity of this facility is unprecedented, and its urgency for the world is paramount,” he continued.

“We are pleased to partner with Citi on this landmark endeavor,” said Assietou Sylla Diouf, Managing Director of Finance & Operations, Gavi. “Never has such a facility been more critical given the crisis we are currently facing. Citi’s presence in over 160 countries and jurisdictions and its expertise will help to ensure the financial mechanics of the COVAX Facility are best able to support COVAX’s ambitious goals of ending the acute phase of the pandemic by the end of 2021.”

Citi remains committed to supporting clients and community partners to help drive a positive socially and environmentally sustainable response to COVID-19. Citi and the Citi Foundation have committed more than $100 million to date in support of COVID-19-related community relief efforts globally. Citi is proud of its efforts to fund stakeholders across multiple United Nations Sustainable Development Goals (SDGs), and is particularly proud of the contribution this work with Gavi will make to SDG 3: Ensure healthy lives and promote well-being for all at all ages.

Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release

A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye